Mylan Inc. (MYL) has launched a generic version of Pfizer Inc.'s (PFE) blockbuster cholesterol Lipitor after receiving approval from the U.S. Food and Drug Administration.

The generic drug-maker will market the widely-prescribed drug as Atorvastatin Calcium Tablets, in 10 miligrams, 20 miligrams, 40 miligrams and 80 miligrams.

Lipitor had U.S. sales of $8.1 billion for the 12 months ended March 31, the company said, citing IMS Health.

Mylan has seen its top line grow in recent quarters as a shaky economy drove customers to low-cost health options, though litigation and restructuring costs have pressured earnings. The company has 171 abbreviated new drug applications pending with U.S. regulators, representing $84 billion in annual sales.

Pfizer, by contrast, has seen its earnings slump 19% in the first full quarter since losing market exclusivity on Lipitor last year. Watson Pharmaceuticals Inc. (WPI) is also selling a generic version of the drug.

Mylan shares were up 19 cents to $21.82 in recent trading. The stock is up 1.7% so far this year.

 
   -By Kristin Jones, Dow Jones Newswires; 212-416-2208; kristin.jones@dowjones.com 
Watson (NYSE:WPI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Watson Charts.
Watson (NYSE:WPI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Watson Charts.